抗VEGF药物玻璃体腔内注射联合23 G玻璃体切除术对增殖性糖尿病视网膜病变患者的疗效分析

目的分析抗血管内皮生长因子(VEGF)药物玻璃体腔内注射联合23 G玻璃体切除术对增殖性糖尿病视网膜病变(PDR)患者的疗效。方法选取2017年1月~2019年1月河南省人民医院88例PDR患者(88只眼),根据治疗方案分组,各44例(44只眼)。对照组给予23 G玻璃体切除术,实验组给予抗VEGF药物玻璃体腔内注射+23 G玻璃体切除术。观察2组手术时间、电凝止血使用率,对比术前术后最佳矫正视力。结果实验组电凝止血使用频率较对照组低,手术时间较对照组短(P<0.05);与对照组比较,术后实验组最佳矫正视力较高(P<0.05);实验组并发症发生率为4.54%,低于对照组18.18%(P<0.05)。结论PDR患者采取抗VEGF药物玻璃体腔内注射和23 G玻璃体切除术联合治疗,可减少并发症,缩短手术时间,提高视力。

Therapeutic effect of intravitreal injection of Anti-VEGF drugs combined with 23 G vitrectomy for patients with proliferative diabetic retinopathy

Objective To analyze the efficacy of intravitreal injection of anti-vascular endothelial growth factor(VEGF)drug combined with 23 G vitrectomy for patients with proliferative diabetic retinopathy(PDR).Methods From January 2017 to January 2019,88 patients with PDR(88 eyes)were enrolled in our hospital.According to the treatment plan,44 patients(44 eyes)were included.The control group was treated with 23 G vitrectomy,and the experimental group was treated with intravitreal injection of anti-VEGF drug and 23 G vitrectomy.The operation time and electrocoagulation hemostasis rate of the two groups were observed,and the best corrected visual acuity was compared before and after surgery.Results The frequency of electrocoagulation and hemostasis in the experimental group was lower than that in the control group.The operation time was shorter than that in the control group(P<0.05).Compared with the control group,the best corrected visual acuity in the experimental group was better(P<0.05).The incidence rate of complications was 4.54%,which was lower than that of the control group by 18.18%(P<0.05).Conclusion PDR patients treated with intravitreal injection of anti-VEGF drugs and 23 G vitrectomy can reduce complications,shorten operation time and improve vision.